Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00305422 |
The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Quetiapine fumarate Drug: Risperidone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Efficacy of Quetiapine Compared to Risperidone on Negative Symptoms and Cognition With Regard to Underlying Neurobiological Mechanisms and Brain Activation. |
Enrollment: | 45 |
Study Start Date: | November 2001 |
Study Completion Date: | January 2003 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
For the subset of subjects for the fMRI investigations the following additional exclusion criteria is valid as:
Study ID Numbers: | 5077/9007 |
Study First Received: | March 20, 2006 |
Last Updated: | December 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00305422 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Neurotransmitter Agents Tranquilizing Agents Risperidone Psychotropic Drugs Central Nervous System Depressants Antipsychotic Agents Serotonin |
Schizophrenia Quetiapine Dopamine Mental Disorders Psychotic Disorders Dopamine Agents Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Risperidone Central Nervous System Depressants Dopamine Antagonists Antipsychotic Agents Pharmacologic Actions |
Schizophrenia Quetiapine Serotonin Antagonists Serotonin Agents Mental Disorders Therapeutic Uses Dopamine Agents Central Nervous System Agents Schizophrenia and Disorders with Psychotic Features |